Operational Costs Compared: SG&A Analysis of Galapagos NV and Novavax, Inc.

A Tale of Two Biotechs: SG&A Expenses Over Time

In the competitive world of biotechnology, operational efficiency is key. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Galapagos NV and Novavax, Inc. from 2014 to 2023. Over this period, Novavax, Inc. has consistently outpaced Galapagos NV in SG&A spending, peaking in 2022 with expenses nearly doubling those of Galapagos NV. Notably, Novavax's SG&A expenses surged by approximately 145% from 2014 to 2023, reflecting its aggressive market strategies and expansion efforts. Meanwhile, Galapagos NV saw a more modest increase of around 940% over the same period, indicating a steady growth trajectory. This divergence in spending patterns highlights differing strategic priorities, with Novavax focusing on rapid scaling and Galapagos NV maintaining a more conservative approach. As the biotech landscape evolves, these financial strategies will play a crucial role in shaping each company's future.